In vitro diagnosis of delayed-type drug hypersensitivity: mechanistic aspects and unmet needs

Dean J Naisbitt; Ryan G Nattrass; Monday O Ogese

doi:10.1016/j.iac.2014.04.009

In vitro diagnosis of delayed-type drug hypersensitivity: mechanistic aspects and unmet needs

Immunol Allergy Clin North Am. 2014 Aug;34(3):691-705, x. doi: 10.1016/j.iac.2014.04.009.

Authors

Dean J Naisbitt¹, Ryan G Nattrass², Monday O Ogese²

Affiliations

¹ Department of Clinical and Molecular Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L69 3GE, England. Electronic address: dnes@liv.ac.uk.
² Department of Clinical and Molecular Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L69 3GE, England.

PMID: 25017686
DOI: 10.1016/j.iac.2014.04.009

Abstract

Several laboratories use the lymphocyte transformation test for the diagnosis of delayed-type drug hypersensitivity reactions. Recently, the availability of multiple readouts has improved our ability to diagnose reactions. It is important to note that most published studies characterizing the usefulness of diagnostic tests utilize blood samples from well-defined test and control patient groups. The purpose of this article is to briefly summarize the cellular and chemical basis of delayed-type drug hypersensitivity reactions and to review in vitro assays that are available for drug hypersensitivity diagnosis.

Keywords: Altered peptide repertoire hypothesis; Delayed-type drug hypersensitivity; Hapten hypothesis; PI hypothesis; T lymphocytes.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Drug Hypersensitivity / diagnosis*
Drug Hypersensitivity / etiology
Humans
Hypersensitivity, Delayed / diagnosis*
Hypersensitivity, Delayed / etiology
Immunoassay / methods
Lymphocyte Activation / immunology
T-Lymphocyte Subsets / immunology

Grants and funding

G0700654/Medical Research Council/United Kingdom